Fig. 3
Responses to the affordability challenges of high-priced potential cures. Note Level of agreement on the above factors was surveyed using a five-point likert scale (1 = strongly disagree, 5 = strongly agree), following focus group interviews to quantitatively summarise the stakeholders’ perspectives in a consistent manner. Values were presented as either percentages or mean (M) with standard deviation (SD), as indicated. Non-pharma includes policy & clinical experts, government payers, civic groups, and patient groups. 1Package deals refer to arrangements that permit charging higher prices for potential cures that have limited clinical evidence at the time of launch, while simultaneously lowering the prices for other medications produced by the same manufacturers